Type 2 Diabetes accounted for a 36.8% share of the global clinical trials within the Metabolic Disorders therapy area in 2020, registering a decrease of 2.9% when compared with the last ten-year average of 39.7% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Type 2 Diabetes
Industry sponsored trials held a 58.9% share of all the clinical trials for Type 2 Diabetes indication in 2020, registering an increase of 14.9% when compared with the ten-year average of 44.0%. Non-industry sponsored trials accounted for a 41.1% share in 2020, marking a decrease of 14.9% over the ten-year average of 56.0%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Type 2 Diabetes trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Type 2 Diabetes trials, accounting for a 69.9% share in 2020, when compared with the five-year average of 59.1% and ten-year average of 54.5%.
Europe was at the second position with a 21.6% share in 2020, over the five-year average of 30.8% and ten-year average of 34.2%, followed by North America with a 14.2% share in 2020, as against five-year and ten-year averages of 27.2% and 34.2% respectively.
Middle East and Africa stood fourth with a 6.1% share in 2020, compared with the five-year average of 9.0% and ten-year average of 10.5%, followed by South and Central America with a 2.0% share in 2020, over five-year and ten-year averages of 6.0% and 8.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Type 2 Diabetes trials, accounting for a 40.9% share in 2020, as against the five-year average of 27.1% and ten-year average of 17.9%.
The US held a 13.2% share in 2020, over the five-year average of 25.3% and ten-year average of 32.0%, followed by Japan with a 9.5% share in 2020, compared with the five-year and ten-year averages of 9.0% and 12.4% respectively.
South Korea held a 9.1% share in 2020, as against the five-year average of 9.8% and ten-year average of 11.0%.
India held an 8.8% share in 2020, over the five-year and ten-year averages of 11.8% and 12.4% respectively.
Top regions of non-industry sponsored Type 2 Diabetes trials
Asia-Pacific was the top region for non-industry sponsored Type 2 Diabetes trials, accounting for a 57.7% share in 2020 when compared with the five-year average of 56.7% and ten-year average of 55.6%.
Europe was at the second position with a 15.9% share in 2020, over the five-year and ten-year averages of 14.7% and 16.7% respectively, followed by Middle East and Africa with a 15.4% share in 2020, as against the five-year average of 17.3% and ten-year average of 13.9%.
North America stood at the fourth position with a 10.1% share in 2020, compared with the five-year average of 10.5% and ten-year average of 13.0%, followed by South and Central America with a 1.0% share in 2020, over the five-year and ten-year averages of 1.2% and 1.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Type 2 Diabetes trials, accounting for a 27.4% share in 2020, as against the five-year average of 14.8% and ten-year average of 11.3%.
India held a 10.6% share in 2020, over the five-year average of 10.6% and ten-year average of 7.6%, followed by Iran with a 10.1% share, compared with the five-year and ten-year averages of 13.7% and 11.1% respectively.
The US held an 8.7% share in 2020, as against the five-year average of 7.9% and ten-year average of 10.3%.
Japan held a 6.3% share in 2020, over the five-year average of 20.4% and ten-year average of 27.1%.
Phase I trials lead industry sponsored clinical trials for Type 2 Diabetes in 2020
Phase I trials held a 57.8% share of industry sponsored clinical trials for Type 2 Diabetes in 2020, over the five-year average of 45.4% and ten-year average of 42.2%.
Phase III trials held a 17.1% share in 2020, as against the five-year average of 19.9% and ten-year average of 23.4%. Phase II trials held a 13.7% share in 2020, compared with the five-year and ten-year averages of 18.0% and 17.4% respectively.
Phase IV trials held an 11.4% share in 2020, over the five-year average of 16.7% and ten-year average of 17.0%.
Phase II trials lead non-industry sponsored clinical trials for Type 2 Diabetes in 2020
Phase II trials held a 37.3% share of non-industry sponsored clinical trials for Type 2 Diabetes in 2020, over the five-year average of 48.5% and ten-year average of 49.1%.
Phase IV trials held a 35.0% share in 2020, as against the five-year average of 31.0% and ten-year average of 31.5%. Phase III trials held a 15.5% share, compared with the five-year and ten-year averages of 13.4% and 12.7% respectively.
Phase I trials held a 12.3% share in 2020, over the five-year average of 7.1% and ten-year average of 6.7%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
